HUM vs PFE: fair value comparison
Humana Inc. and Pfizer Inc. · Updated 2026-09-12
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, PFE currently sits closer to the top of our discount ranking. PFE carries the stronger quality grade.
| HUM | PFE | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $409.80 | $27.72 |
| 12-month range | $176.95–$394.88 | $24.23–$28.55 |
| Sector rank | #110 of 113 Healthcare | #103 of 113 Healthcare |
| Quality grade | F | D |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Expanding |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Fairly Valued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: HUM fair value analysis · PFE fair value analysis